BME · BlackRock Health Sciences Trust
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BME
this stock
BlackRock Health Sciences Trust
|
$577.06M | +12.2% | — | — | 0.3% |
|
BLK
BlackRock, Inc.
|
$375.82B | +8.1% | +16.2% | 27.7 | 0.7% |
|
BX
Blackstone Inc.
|
$107.62B | -7.0% | +9.2% | 32.2 | 3.5% |
|
KKR
KKR & Co. Inc.
|
$97.38B | -14.9% | -11.0% | — | 1.6% |
|
BN
BROOKFIELD Corp /ON/
|
$93.07B | -9.2% | — | — | 0.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BME | +4.5% | +7.7% | +8.3% | +6.1% | +12.2% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +5.9% | +4.0% | -3.3% | +3.6% | -0.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.